AFT Stock Overview
AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Asia, and internationally.
AFT Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$3.36|
|52 Week High||NZ$5.00|
|52 Week Low||NZ$3.10|
|1 Month Change||-1.18%|
|3 Month Change||-7.69%|
|1 Year Change||-19.04%|
|3 Year Change||10.16%|
|5 Year Change||34.40%|
|Change since IPO||8.39%|
Recent News & Updates
|AFT||NZ Pharmaceuticals||NZ Market|
Return vs Industry: AFT exceeded the NZ Pharmaceuticals industry which returned -24.7% over the past year.
Return vs Market: AFT underperformed the NZ Market which returned -17% over the past year.
|AFT Average Weekly Movement||4.3%|
|Pharmaceuticals Industry Average Movement||10.5%|
|Market Average Movement||3.8%|
|10% most volatile stocks in NZ Market||8.0%|
|10% least volatile stocks in NZ Market||2.7%|
Stable Share Price: AFT is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AFT's weekly volatility (4%) has been stable over the past year.
About the Company
AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, eyecare, first aid, pain management, gastrointestinal, dermatology, and medicated vitamins. The company was incorporated in 1997 and is headquartered in Auckland, New Zealand.
AFT Pharmaceuticals Fundamentals Summary
|AFT fundamental statistics|
Is AFT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AFT income statement (TTM)|
|Cost of Revenue||NZ$68.54m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.19|
|Net Profit Margin||15.23%|
How did AFT perform over the long term?See historical performance and comparison
Is AFT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AFT?
Other financial metrics that can be useful for relative valuation.
|What is AFT's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does AFT's PE Ratio compare to its peers?
|AFT PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ACMELAB ACME Laboratories
2348 Dawnrays Pharmaceutical (Holdings)
524558 Neuland Laboratories
A001630 Chong Kun Dang Holdings
AFT AFT Pharmaceuticals
Price-To-Earnings vs Peers: AFT is good value based on its Price-To-Earnings Ratio (17.8x) compared to the peer average (39.1x).
Price to Earnings Ratio vs Industry
How does AFT's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: AFT is good value based on its Price-To-Earnings Ratio (17.8x) compared to the Global Pharmaceuticals industry average (20.5x)
Price to Earnings Ratio vs Fair Ratio
What is AFT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||17.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AFT's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AFT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AFT (NZ$3.36) is trading above our estimate of fair value (NZ$3.09)
Significantly Below Fair Value: AFT is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is AFT Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFT's forecast earnings growth (13% per year) is above the savings rate (2.1%).
Earnings vs Market: AFT's earnings (13% per year) are forecast to grow faster than the NZ market (5.9% per year).
High Growth Earnings: AFT's earnings are forecast to grow, but not significantly.
Revenue vs Market: AFT's revenue (13.5% per year) is forecast to grow faster than the NZ market (5.6% per year).
High Growth Revenue: AFT's revenue (13.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AFT's Return on Equity is forecast to be high in 3 years time (24.1%)
Discover growth companies
How has AFT Pharmaceuticals performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AFT has high quality earnings.
Growing Profit Margin: AFT's current net profit margins (15.2%) are higher than last year (6.7%).
Past Earnings Growth Analysis
Earnings Trend: AFT has become profitable over the past 5 years, growing earnings by 66.7% per year.
Accelerating Growth: AFT's earnings growth over the past year (161.4%) exceeds its 5-year average (66.7% per year).
Earnings vs Industry: AFT earnings growth over the past year (161.4%) exceeded the Pharmaceuticals industry 8.9%.
Return on Equity
High ROE: AFT's Return on Equity (35%) is considered high.
Discover strong past performing companies
How is AFT Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AFT's short term assets (NZ$77.5M) exceed its short term liabilities (NZ$29.1M).
Long Term Liabilities: AFT's short term assets (NZ$77.5M) exceed its long term liabilities (NZ$36.0M).
Debt to Equity History and Analysis
Debt Level: AFT's net debt to equity ratio (51.6%) is considered high.
Reducing Debt: AFT's debt to equity ratio has reduced from 120.7% to 65.6% over the past 5 years.
Debt Coverage: AFT's debt is well covered by operating cash flow (38%).
Interest Coverage: AFT's interest payments on its debt are well covered by EBIT (8.4x coverage).
Discover healthy companies
What is AFT Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AFT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AFT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AFT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AFT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AFT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Hartley Atkinson, M.Pharm (Dist), PhD, is Co-Founder of AFT Pharmaceuticals Limited in 1997. Dr. Atkinson is Chief Executive Officer of AFT Pharmaceuticals Limited since September 04, 1997 and also ser...
CEO Compensation Analysis
Compensation vs Market: Hartley's total compensation ($USD484.21K) is below average for companies of similar size in the NZ market ($USD748.55K).
Compensation vs Earnings: Hartley's compensation has been consistent with company performance over the past year.
Experienced Board: AFT's board of directors are considered experienced (8.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|12 Jan 22||BuyNZ$66,209||Jon Lamb||Individual||15,000||NZ$4.44|
|17 Dec 21||BuyNZ$170,814||Jon Lamb||Individual||40,670||NZ$4.20|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
AFT Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: AFT Pharmaceuticals Limited
- Ticker: AFT
- Exchange: NZSE
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NZ$352.351m
- Shares outstanding: 104.87m
- Website: https://www.aftpharm.com
Number of Employees
- AFT Pharmaceuticals Limited
- 129 Hurstmere Road
- Level 1
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AFT||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Dec 2015|
|AFP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
|AFP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/26 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.